Day: September 11, 2020

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a business update and report its financial results for the first half 2020 on Thursday, September 17, 2020. Following the announcement, Auris Medical’s management team will host a live conference call and webcast at 8:30 am Eastern Time (2:30 pm Central European Time).To participate in this conference call, dial 1-877-870-9135 (US toll free) or +44 2071 928 338 (international), and enter passcode 5286195. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will...

NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) — Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) today provided a business update and supplemental information ahead of the J.P. Morgan Gaming, Lodging, Restaurant & Leisure Management Access Forum (September 14-15) and Bank of America Global Real Estate Conference (September 16-17). The supplement can be located on the company’s website under Investor Relations Home / News & Events / Presentations & Transcripts (http://ir.rymanhp.com/index.php/events-and-presentations/presentations).The Company will present virtually to investors attending the J.P. Morgan Gaming, Lodging, Restaurant & Leisure Management Access Forum, on Monday, September 14, at 2:10 p.m. ET. Colin Reed, Chairman and Chief Executive Officer will participate in an analyst-led fireside...

PITTSBURGH, Sept. 11, 2020 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, announced today that the Company will participate in the following event:Deutsche Bank Virtual Technology ConferenceDate: Tuesday, September 15, 2020Time: 4:00 p.m. EDTPlace: VirtualParticipantsDr. Chuck Mattera, Chief Executive Officer, II-VIMary Jane Raymond, Chief Financial Officer, II-VIA real-time webcast of the discussion can be accessed via the Investors section of the II-VI website at https://www.ii-vi.com/investors-events/.About II-VI IncorporatedII-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials...

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL’s study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting.Data show that VBL’s anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolated from all MS patients included in the study (n=33) by up to 97%, regardless of disease severity, gender or active treatment. Notably, the activity was seen not only in the monocytes from relapsing-remitting, but also those from primary progressive and secondary progressive patients with high Expanded Disability Status Scale (EDSS) scores of 5.5-6.5.“We...

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Friday, September 18, 2020 at 8:00 a.m. ET and host investor meetings.To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.About Oyster Point PharmaOyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular...

BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.Presentation details:Date: Wednesday, September 16, 2020Time: 1:30-1:50pm EDTA live webcast of the presentation will be available on the Investors section of the company’s website: www.electrocore.comAbout electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative...

Premium 5 is First to Market With Its Live Resin and Live Resin X Vape CartridgesRadient Adds Provincial Registrations in Alberta, Manitoba and SaskatchewanEDMONTON, Alberta, Sept. 11, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), and Premium 5 Ltd. (“Premium 5”) are pleased to announce that the Company has successfully completed its first shipment of products to the BC Liquor Distribution Branch (the “BCLDB “), with Premium 5 products now available across British Columbia, including the first live resin based vape cartridges in Canada.Radient anticipates further purchase orders imminently, following recent completion of the provincial registration process in Alberta, Saskatchewan and Manitoba. The Company is working with additional provincial boards to register...

RALEIGH, N.C., Sept. 11, 2020 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the presentation of five scientific posters highlighting data regarding BELBUCA at the 14th Annual PAINWeek 2020 National Conference on Pain Management taking place virtually September 11-13, 2020.Poster Presentations:A Phase I Placebo-Controlled Trial Comparing the Effect of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride: PupillometryAuthors: Lynn Webster, MD; Jacqueline Cater, PhD; Thomas Smith, MDSecondary Outcomes of a Phase I Placebo-Controlled Trial Comparing the Effect of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory DriveAuthors: Lynn Webster, MD; Jacqueline...

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m. ET.A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare...

VANCOUVER, British Columbia, Sept. 11, 2020 (GLOBE NEWSWIRE) — Juggernaut Exploration Ltd. (TSX-V: JUGR) (OTCQB: JUGRF) (FSE: 4JE) (the “Company” or “Juggernaut”) is pleased to report it has received TSX approval to earn a 100% interest in the Goldstar property announced July 7th 2020 (Link to July 7thNews) containing 238 hectares located in West Central BC in close proximity to infrastructure and the Goldstandard property providing for cost effective exploration. Shareholder approval for the issuance of greater than 10% of the issued and outstanding shares to the DSM Syndicate collectively will be sought at the Company’s AGM in December.  The Goldstar property Goldilocks Zone has provided excellent results to date containing assays of 7.86g/t AuEq over 3.75m true width. This channel was taken in 2019 over a 3.75m wide section to...